Last update Nov. 4, 2018
We do not have alternatives for C59 H90 O4.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C59 H90 O4 is Coenzyme Q10 in Molecular formula.Is written in other languages:
C59 H90 O4 is also known as
C59 H90 O4 belongs to these groups or families:
Main tradenames from several countries containing C59 H90 O4 in its composition:
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Present in the cells of all organisms, animals and plants, in the mitochondrial membrane. A powerful fat-soluble antioxidant.
It is synthesized in the body’s cells and is also obtained from diet (Niklowitz 2005), mainly from the consumption of meat, where it is very abundant, or from commercial supplements.
Indicated in the congenital deficiency of coenzyme Q, in some heart diseases and, off label, it is used in neurodegenerative diseases, headaches, cancer and others. Also sold as an "anti-aging" product. The evidence of its efficacy in most indications is zero, scarce or has little foundation (NIH 2018 and 2017, Hernández 2018).
Since the last update we have not found published data on its excretion in breast milk.
It is found naturally in breastmilk (Tang 2006), in greater amounts in colostrum and transition milk than in mature milk and preterm mother's milk (Quiles 2006, Niklowitz 2005).
Its pharmacokinetic data (large volume of distribution and moderately high molecular weight) make it unlikely it will transfer to breastmilk in significant quantities from the exogenous supply. Its liposolubility could make greater excretion in breastmilk possible.
The exogenous supply of Coenzyme-Q10 seems to increase its concentration in breastmilk (Codoñer 2013) and in infant plasma (Compagnoni 2004).
It is considered virtually devoid of toxicity and with few side effects (gastrointestinal ones) even at very high doses (Huntington 2010).
The amount contained in breastmilk, between 0.3 and 1.6 mg/L (Quiles 2006, Niklowitz 2005, Compagnoni 2004) is insufficient to reach the dosage normally used in newborns or infants: 15 mg/kg up to a maximum of 200 to 300 mg/day (Comité 2015, Lucangioli 2013).
Given its lack of toxicity, the fact it is a normal component of the body and the scarce increase in concentration in breastmilk that is assumed with supplements, its use during breastfeeding does not appear to be contraindicated.